ArticleFrontiers in oncology2021

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.

Xuan Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.